Patent & Trade Mark
Karin Innes
Karin Innes
Senior Associate

Level 14, 90 Collins Street
Melbourne VIC 3000
Tel +61 3 8618 4118
Fax +61 3 8618 4199
Recent Publications
18 Oct 2016
The Australian Patent Office (APO) has determined that claims directed to a composition comprising double-stranded RNA (so-called “interfering RNA” or “iRNA”) is a manner of manufacture (patent eligible subject matter) in accordance with Section 18(1)(a) of the Patents Act.

16 Mar 2016
For US patent applications filed post introduction of the America Invents Act (AIA) (which changed from first-to-invent to first-to-file), sale and offer for sale made in confidence of a product that is subsequently patented will not count as prior disclosure in the United States. Put simply, secret use is not prior art for post-AIA applications.

03 Sep 2015
The High Court on 2 September 2015 handed down its decision in the appeal by AstraZeneca against a finding of the Full Federal Court that the claims of its Australian Patent were invalid for being obvious. A copy of the decision can be found here. The High Court decision is consistent with that of the Full Federal Court. Generic companies that have already been marketing generic version of rosuvastatin will no doubt be breathing a collective sigh of relief in the wake of this decision.
Karin is a Senior Associate with FB Rice.  She qualified as a patent attorney in 2002 and joined FB Rice in 2007 after working within the patent attorney practices of two large Australian law firms.
Karin regularly practices in the preparation, filing and prosecution of patent applications on behalf of local Australian clients as well as corporate clients and foreign agents before the Australian and New Zealand Patent Offices as well as the prosecution of patent application on behalf of local Australian clients and licensees before a number of different jurisdictions throughout the world.
She also manages international patent portfolios for local Australian clients and regularly conducts patent strategy, patentability, infringement, due diligence and freedom to operate analysis.   Her past experience working in a large biotechnology company has given her an in-depth understanding of the commercial drivers that underlie research and development strategies within biotechnology and pharmaceutical companies and her drafting and prosecution strategies are tailored with this focus in mind.  Further, her particular experience in clinical oncology provides a unique practical understanding of the application of basic research.
Additionally, Karin has acted in a technology advisory capacity to brief counsel for contentious patent litigation matters and has conducted discovery.  She has also managed a number of patent oppositions before the Australian and New Zealand patent offices on behalf of the Applicant and Opponent.  Her clients range from universities and academic research institutes to start-ups and large biotechnology and pharmaceutical companies.
While Karin has experience across a number of technology areas including gene cloning, gene expression and silencing, yeast biology, immunology, microbiology, cell biology, intracellular signalling and diagnostics, her particular area of expertise are focussed on antibodies and stem cell biology (including mesenchymal stem cell, cardiac stem cells and ES cells).
Karin's PhD research which was undertaken at the prestigious Walter and Eliza Hall Institute for Medical Research focussed on strategies to generate immortalised murine haemopoietic stem cells.  Following her PhD, Karin worked in clinical oncology research for Amgen Australia where she managed phase I, II and III clinical trials.
Karin has published papers in both the scientific and legal media.  She regularly contributes articles to the FB Rice website and conducts client seminars.  She is a member of AusBiotech and Intellectual Property Society of Australia and New Zealand (IPSANZ) and a Fellow of the Institute of Patent and Trademark Attorneys of Australia.
Karin is a registered Australian and New Zealand Patent and Trade Marks Attorney.


  • BSc (Hons) from the University of Melbourne, with a double major in microbiology and biochemistry
  • PhD from Walter and Eliza Hall Institute for Medical Research focusing on the use of oncogenes to generate immortal murine stem cell lines

Key Areas of Expertise

  • Stem cells
  • Cell biology
  • Immunology
  • Gene silencing
  • Microbiology

Industry Focus

Professional Affiliations
  • Fellow of the Institute of Patent and Trade Mark Attorneys of Australia
  • Member of the Intellectual Property Society of Australia and New Zealand (IPSANZ)
  • Committee member of the Intellectual Property Society of Australia and New Zealand (IPSANZ)